Table 1.

IC₅₀s of oxaliplatin in HCT116 and A549 cancer cells in the absence and presence of WLR treatment

Treatment	IC50s (μg/mL)
	HCT116	A549
L-OHP	1.05 ± 0.07	6.94 ± 0.78
L-OHP + Vehicle	0.97 ± 0.01	5.83 ± 0.02
L-OHP + WLR (10 μg/mL)	0.98 ± 0.06	6.76 ± 0.00
L-OHP + WLR (30 μg/mL)	1.00 ± 0.02	7.66 ± 1.25
L-OHP + WLR (100 μg/mL)	0.98 ± 0.02	6.50 ± 0.30